U.S. Food and Drug Administration staff are recommending new warnings about psychiatric events observed in some patients taking Roche Holding AG’s Tamiflu and GlaxoSmithKline Plc’s Relenza, according to documents released on Friday. Full Story
About OODA Analyst
OODA is comprised of a unique team of international experts capable of providing advanced intelligence and analysis, strategy and planning support, risk and threat management, training, decision support, crisis response, and security services to global corporations and governments.